Attention deficit hyperactivity disorder

Intelligent.com Announces Best Online Masters in Educational Psychology Degree Programs for 2021

Wednesday, May 5, 2021 - 8:15pm

b'SEATTLE, May 5, 2021 /PRNewswire-PRWeb/ -- Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the top online programs for 2021.

Key Points: 
  • b'SEATTLE, May 5, 2021 /PRNewswire-PRWeb/ -- Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the top online programs for 2021.
  • The comprehensive research guide is based on an assessment of 1,280 accredited colleges and universities in the nation.
  • Each program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment.
  • In addition to accessibility and cost, the steady job growth in this market is one of the many reasons Intelligent.com researched and ranked the Top Online Masters in Educational Psychology Degree Programs.\nIntelligent.com analyzed 150 schools, on a scale of 0 to 100, with only 7 making it to the final list for Online Masters in Educational Psychology Degree Programs.

NLS Pharmaceutics Announces Patent Issuance in Europe for its Mazindol Controlled-Release Formulation (Mazindol CR)

Wednesday, May 5, 2021 - 1:30pm

EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • EP3426232, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "Earlier this year, we were granted a similar patent in Canada, and our U.S. patent application is pending review.
  • Additionally, this newly issued patent augments the Orphan Drug Designations that we have for Quilience in both Europe and the U.S.
  • The Company\'s lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children

Tuesday, May 4, 2021 - 10:30pm

The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.

Key Points: 
  • The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors.
  • In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant.
  • "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient.
  • In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents.

Supernus to Host First Quarter 2021 Financial Results Conference Call

Tuesday, April 27, 2021 - 10:44pm

b'Following the live call, a replay will be available on the Company\xe2\x80\x99s website, www.supernus.com , under the Investor Relations section.

Key Points: 
  • b'Following the live call, a replay will be available on the Company\xe2\x80\x99s website, www.supernus.com , under the Investor Relations section.
  • The webcast will be available on the Company\xe2\x80\x99s website for 60 days following the live call.\nSupernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.\nOur diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson\xe2\x80\x99s disease, cervical dystonia and chronic sialorrhea.
  • We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson\xe2\x80\x99s disease, epilepsy, depression, and rare CNS disorders.
  • For more information, please visit www.supernus.com .\n'

OWP Pharmaceuticals Announces Patent Application for the First-Ever Oral Liquid Formulation of Atomoxetine Hydrochloride for the Treatment of Attention Deficit Hyperactivity Disorder

Thursday, April 22, 2021 - 1:00pm

b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.

Key Points: 
  • b"NAPERVILLE, Ill., April 22, 2021 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc. is a privately held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and commercializing novel oral liquid formulations.
  • OWP announced today that it has submitted for U.S. patent protection, for the first-ever oral suspension of atomoxetine hydrochloride.
  • The medication is widely prescribed by healthcare providers in psychiatry for ADHD, and it is indicated for treatment in children 6 years and older and adults.
  • Some individuals with ADHD also display difficulty regulating emotions or problems with executive function.

New Survey: Americans Expect Companies to End Discriminatory Hiring Practices; Kelly® Finds More Employers Ready to Hire Neurodiverse Talent

Monday, April 5, 2021 - 6:51pm

Kelly President and CEO Peter Quigley agrees and says employers are showing more interest in hiring and supporting neurodiverse talent than at any time in his career.

Key Points: 
  • Kelly President and CEO Peter Quigley agrees and says employers are showing more interest in hiring and supporting neurodiverse talent than at any time in his career.
  • Our Kelly Discover solution helps companies engage with undiscovered talent communities, including talent on the autism spectrum, to identify exceptional and available resources, said Quigley.
  • A more inclusive workforce is central to our Equity@Work initiative aimed at connecting more people to enriching work.
  • New survey results from Kelly show Americans overwhelmingly support opening doors to neurodiverse talent and they want employers to do the same:
    81% say companies should do more to remove barriers discriminatory hiring policies or practices that keep people from being hired or promoted.

NLS Pharmaceutics Appoints Silvia Panigone, Ph.D. As Chief Operating Officer

Monday, April 5, 2021 - 1:30pm

STANS, Switzerland, April 5, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the appointment of Silvia Panigone, Ph.D., eMBA as Chief Operating Officer.

Key Points: 
  • STANS, Switzerland, April 5, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the appointment of Silvia Panigone, Ph.D., eMBA as Chief Operating Officer.
  • All of us at NLS extend a warm welcome to Silvia."
  • Prior to joining NLS, Dr. Panigone was managing director of ADYA Consulting Sagl, a Swiss investment boutique in the life sciences sector operating globally and supporting companies in their corporate strategy and fundraising.
  • NLS completed a phase 2 study in the U.S. evaluating mazindol CR in adult subjects with ADHD.

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Friday, April 2, 2021 - 9:58pm

Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.

Key Points: 
  • Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.
  • This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Jonathan Covey MD, JD is recognized by Continental Who's Who

Tuesday, March 30, 2021 - 8:36pm

COLORADO SPRINGS, Colo., March 30, 2021 /PRNewswire/ --Jonathan Covey MD, JD, is being recognized by Continental Who's Who as a Top Psychiatrist for his professional excellence in the field of Psychiatry and his outstanding leadership within his practice.

Key Points: 
  • COLORADO SPRINGS, Colo., March 30, 2021 /PRNewswire/ --Jonathan Covey MD, JD, is being recognized by Continental Who's Who as a Top Psychiatrist for his professional excellence in the field of Psychiatry and his outstanding leadership within his practice.
  • Covey is currently offering telemedicine services in the state of Colorado.
  • He offers a vast repertoire of valuable knowledge and experience in mood disorders, anxiety, bipolar, ADHD, depression, anxiety, PTSD, and more.
  • Covey completed his undergraduate studies at Sanford University and received his Juris Doctor degree.

NLS Pharmaceutics Announces Issuance of Canadian Patent Covering its Novel Formulation of Controlled-Release Mazindol (Mazindol CR)

Monday, March 29, 2021 - 1:30pm

3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).

Key Points: 
  • 3016852, entitled A MAZINDOL IR/SR MULTILAYER TABLET AND ITS USE FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD).
  • "We are very pleased to have obtained the first patent covering our novel formulation of controlled-release mazindol as we advance the development of Quilience to treat narcolepsy and other potential sleep-wake disorders," said Alex Zwyer, Chief Executive Officer of NLS.
  • "Our application for a similar patent in Europe received notice of allowance in January, and our U.S. patent application is pending review.
  • The Company's lead product candidate, Quilience is a proprietary controlled-release formulation of mazindol (mazindol CR), and is being developed for the treatment of narcolepsy.